TENX reports levosimendan biomarker gains in higher-burden PH-HFpEF
Levosimendan in PH-HFpEF patients with higher baseline disease burden showed significant clinical and biomarker improvements, especially with lower baseline 6MWD, despite not meeting the primary endpoint overall; safety was acceptable and LEVEL insights guide a refined LEVEL-2 trial.
Levosimendan showed significant clinical and biomarker improvements in PH-HFpEF patients with greater baseline disease burden, especially those with lower baseline 6MWD, even though the study did not meet its primary endpoint in the overall population. Safety was acceptable, and insights from LEVEL are guiding a…